Clinical trial
A Phase I Open-label Study to Assess the Safety, Tolerability and Potential Efficacy of a Novel Tracheal Replacement Consisting of a Tissue-engineered Decellularised Tracheal Scaffold With Seeded Autologous Mesenchymal Cells in Subjects With Severe Tracheal Stenosis or Malacia
NCT02949414 is registered in ClinicalTrials.gov with Cell Therapy Catapult as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Open-label Study to Assess the Safety, Tolerability and Potential Efficacy of a Novel Tracheal Replacement Consisting of a Tissue-engineered Decellularised Tracheal Scaffold With Seeded Autologous Mesenchymal Cells in Subjects With Severe Tracheal Stenosis or Malacia
- Lead sponsor
- Cell Therapy Catapult
- Phase
- Phase 1
- Overall status
- Suspended
- Start date
- September 30, 2016
- Completion date
- September 30, 2024
- Enrollment
- 4 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.